Jazz Pharmaceuticals to expand Irish workforce across Dublin, Athlone sites
pharmafile | August 6, 2018 | News story | Manufacturing and Production, Sales and Marketing | Dublin, Ireland, jazz pharmaceuticals, pharma
Jazz Pharmaceuticals has announced its intention to expand its staff numbers at two of its bases in its home country of Ireland, growing its total workforce of 150 in the country by 10%.
The company said that it would be adding staff to its global headquarters in the capital of Dublin, as well as at its manufacturing plant in Athlone, and is actively recruiting to this end.
The move is one of a number of expansion efforts as the firm files for European regulatory approval on its candidate for the treatment of narcolepsy and sleep apnoea. As noted by Chairman and Chief Executive Bruce Cozadd, Jazz is ramping up its R&D budget to hit $200 million this year – 12% of its revenue – and has placed its turnover projections at $1.9 billion thanks to growth in new and existing products.
“Our existing drugs that are on market, plus our R&D pipeline, should produce good ongoing growth for the company,” Cozadd explained. “In addition to that, we’ve a track record of bringing additional drugs into the company through acquisitions and partnerships. Because the company has good profitability and cash flow and a strong balance sheet.”
The company is also pushing other treatments which it hoeps will drive this growth, including candidates for Parkinson’s and acute myeloid leukaemia in adults, the latter of which received a positive recommendation from the Committee for Medicinal Products for Human Use (CHMP) earlier this year.
Matt Fellows
Related Content
Smurfit Westrock unveils new clinical packaging facility at Dublin Airport
Smurfit Westrock has inaugurated the first-of-its-kind adherence and clinical packaging facility, reinforcing Ireland’s role at …
LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …
Johnson & Johnson announces successful results from trial for myeloma treatment
Global healthcare company, Johnson & Johnson, announced that analysis of its Darzalex (daratumumab) therapy showed …
